IFNA1 and systemic lupus erythematosus: Clinical evidences, in lupus patients, with elevated type I IFN in serum (38), and in patients that receive treatment for chronic hepatitis C infections and cancer (39, 40), show that peripheral IFN-α produce CNS alterations.